Persistently Activated Stat3 Maintains Constitutive NF-κB Activity in Tumors

Cancer Cell

Volumn 15, Issue 4, 2009, Pages 283-293

  Lee, Heehyoung ^a   Herrmann, Andreas ^a   Deng, Jie Hui ^a   Kujawski, Maciej ^a   Niu, Guilian ^b   Li, Zhiwei ^b   Forman, Steve ^a   Jove, Richard ^a   Pardoll, Drew M ^c   Yu, Hua ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

CELLCYCLE

Indexed keywords

I KAPPA B KINASE; STAT3 PROTEIN; TRANSCRIPTION FACTOR RELA;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL NUCLEUS TRANSPLANTATION; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSFECTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH;

MURINAE;

EID: 63249092765     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2009.02.015     Document Type: Article

References (45)

1. Bollrath J., Phesse T.J., von Burstin V.A., Putoczki T., Bennecke M., Bateman T., Nebelsiek T., Lundgren-May T., Canli O., Schwitalla S., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15 (2009) 91-102
2. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., and Darnell Jr. J.E. Stat3 as an oncogene. Cell 98 (1999) 295-303
3. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J.L., Nunez G., et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10 (1999) 105-115
4. Chen L.F., and Greene W.C. Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J. Mol. Med. 81 (2003) 549-557
5. Chen L.F., and Greene W.C. Shaping the nuclear action of NF-kappaB. Nat. Rev. Mol. Cell Biol. 5 (2004) 392-401
6. Chen L.F., Fischle W., Verdin E., and Greene W.C. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293 (2001) 1653-1657
7. Chen L.F., Mu Y., and Greene W.C. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J. 21 (2002) 6539-6548
8. Chen L.F., Williams S.A., Mu Y., Nakano H., Duerr J.M., Buckbinder L., and Greene W.C. NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol. Cell. Biol. 25 (2005) 7966-7975
9. Dalwadi H., Krysan K., Heuze-Vourc'h N., Dohadwala M., Elashoff D., Sharma S., Cacalano N., Lichtenstein A., and Dubinett S. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin. Cancer Res. 11 (2005) 7674-7682
10. Darnell Jr. J.E. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2 (2002) 740-749
11. Deng W.G., and Wu K.K. Regulation of inducible nitric oxide synthase expression by p300 and p50 acetylation. J. Immunol. 171 (2003) 6581-6588
12. Deo D.D., Axelrad T.W., Robert E.G., Marcheselli V., Bazan N.G., and Hunt J.D. Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells. Evidence for a dual kinase mechanism. J. Biol. Chem. 277 (2002) 21237-21245
13. Ghosh S., May M.J., and Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16 (1998) 225-260
14. Giraud S., Bienvenu F., Avril S., Gascan H., Heery D.M., and Coqueret O. Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a. J. Biol. Chem. 277 (2002) 8004-8011
15. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., Kagnoff M.F., and Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
16. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., and Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15 (2009) 103-113
17. Hu M.C., Lee D.F., Xia W., Golfman L.S., Ou-Yang F., Yang J.Y., Zou Y., Bao S., Hanada N., Saso H., et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117 (2004) 225-237
18. Huang T.T., Kudo N., Yoshida M., and Miyamoto S. A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. Proc. Natl. Acad. Sci. USA 97 (2000) 1014-1019
19. Karin M., and Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5 (2005) 749-759
20. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2 (2002) 301-310
21. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., Niu G., Kay H., Mule J., Kerr W.G., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11 (2005) 1314-1321
22. Kortylewski M., Xin H., Kujawski M., Lee H., Liu Y., Harris T., Drake C., Pardoll D., and Yu H. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15 (2009) 114-123
23. Kujawski M., Kortylewski M., Lee H., Herrmann A., Kay H., and Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 118 (2008) 3367-3377
24. Lee C.K., Raz R., Gimeno R., Gertner R., Wistinghausen B., Takeshita K., DePinho R.A., and Levy D.E. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 17 (2002) 63-72
25. Lee D.F., Kuo H.P., Chen C.T., Hsu J.M., Chou C.K., Wei Y., Sun H.L., Li L.Y., Ping B., Huang W.C., et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130 (2007) 440-455
26. Lenz G., Davis R.E., Ngo V.N., Lam L., George T.C., Wright G.W., Dave S.S., Zhao H., Xu W., Rosenwald A., et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319 (2008) 1676-1679
27. Lo H.W., Hsu S.C., Ali-Seyed M., Gunduz M., Xia W., Wei Y., Bartholomeusz G., Shih J.Y., and Hung M.C. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7 (2005) 575-589
28. Lu T., and Stark G.R. Cytokine overexpression and constitutive NFkappaB in cancer. Cell Cycle 3 (2004) 1114-1117
29. Lu T., Sathe S.S., Swiatkowski S.M., Hampole C.V., and Stark G.R. Secretion of cytokines and growth factors as a general cause of constitutive NFkappaB activation in cancer. Oncogene 23 (2004) 2138-2145
30. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., and Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317 (2007) 121-124
31. Niu G., Bowman T., Huang M., Shivers S., Reintgen D., Daud A., Chang A., Kraker A., Jove R., and Yu H. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21 (2002) 7001-7010
32. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., and Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
33. Pomerantz J.L., Denny E.M., and Baltimore D. CARD11 mediates factor-specific activation of NF-kappaB by the T cell receptor complex. EMBO J. 21 (2002) 5184-5194
34. Pranada A.L., Metz S., Herrmann A., Heinrich P.C., and Muller-Newen G. Real time analysis of STAT3 nucleocytoplasmic shuttling. J. Biol. Chem. 279 (2004) 15114-15123
35. Schuringa J.J., Schepers H., Vellenga E., and Kruijer W. Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL-6 stimulation. FEBS Lett. 495 (2001) 71-76
36. Stancovski I., and Baltimore D. NF-kappaB activation: the I kappaB kinase revealed?. Cell 91 (1997) 299-302
37. Turkson J., Zhang S., Palmer J., Kay H., Stanko J., Mora L.B., Sebti S., Yu H., and Jove R. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol. Cancer Ther. 3 (2004) 1533-1542
38. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., Bhattacharya R., Gabrilovich D., Heller R., Coppola D., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10 (2004) 48-54
39. Welte T., Zhang S.S., Wang T., Zhang Z., Hesslein D.G., Yin Z., Kano A., Iwamoto Y., Li E., Craft J.E., et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc. Natl. Acad. Sci. USA 100 (2003) 1879-1884
40. Xiao H., Chung J., Kao H.Y., and Yang Y.C. Tip60 is a co-repressor for STAT3. J. Biol. Chem. 278 (2003) 11197-11204
41. Yang J., Liao X., Agarwal M.K., Barnes L., Auron P.E., and Stark G.R. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev. 21 (2007) 1396-1408
42. Yu H., and Jove R. The STATs of cancer--new molecular targets come of age. Nat. Rev. Cancer 4 (2004) 97-105
43. Yu H., Kortylewski M., and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7 (2007) 41-51
44. Yu Z., and Kone B.C. The STAT3 DNA-binding domain mediates interaction with NF-kappaB p65 and iuducible nitric oxide synthase transrepression in mesangial cells. J. Am. Soc. Nephrol. 15 (2004) 585-591
45. Zhong Z., Wen Z., and Darnell Jr. J.E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264 (1994) 95-98